Posts | Mounjaro News - Actualite tirzepatide

Leerink relève son objectif de cours pour Eli Lilly en raison des perspectives de croissance liées à un médica

Lilly's Mounjaro (tirzepatide), a GIP/GLP-1 dual agonist, demonstrated cardiovascular protection in landmark head-to-head trial, reinforcing its benefit in patients with type 2 diabetes and heart disease

GLP-1s. What should you know? - Community Reporter

Lilly’s GLP-1 windfall fuels M&A ‘land grab’ across 10 deals, $25B - BioWorld News

Lilly launches its LillyDirect sales channel in the UK

Clinical Implications of Mounjaro (Tirzepatide) for Breast Cancer Detection and Management: A Narrative Review

Big obesity bets and China's rise fuel potential $2T in 2032 drug sales: Evaluate - Fierce Pharma

Lilly’s tirzepatide will be biggest blockbuster ever, topping $70B by 2032: Evaluate

What is Mounjaro? And does it work better for weight loss than Ozempic and Wegovy?

Wegovy, Zepbound: Guideline advises GLP-1s as first-line obesity drugs - Medical News Today